FundedIQ
Biotechnology

DeepCyte: Funding, Investors & Team (Sep 2026)

DeepCyte is a biotechnology company that offers predictive products for toxicology using single-cell metabolomics technology.

www.deepcyte.bio LinkedIn Wilmington, United States 1-10 employees
Biopharma Biotechnology Life Science
Total raised
$1.5M
Rounds
1
Latest
Seed
Apr 2026

DeepCyte has raised $1.5M across 1 funding round on record, the most recent a Seed of $1.5M announced in Apr 2026.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

DeepCyte Company Profile and Key Stats

Total funding raised
$1.5M
across 1 round on record
Funding rounds on record
1
Latest funding round
Seed
$1.5M in Apr 2026
Employees
1-10
reported band
Headquarters
Wilmington, United States

Latest funding round on record: Apr 2026.

DeepCyte Funding Rounds

Date
Round
Amount
Seed
$1.5M

DeepCyte Founders and Leadership Team

Name
Role
Contact
Theodore Alexandrov
Founder

No contact details are on record for this team yet.

DeepCyte Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,179
$8.0M
29,722
$7.5M
16,485
$3.1M

DeepCyte's latest round of $1.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like DeepCyte in Biotechnology and Wilmington

Companies Similar to DeepCyte

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…

Series A $6.3M

Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.

Series C $90.0M

Cataract surgery is the single most common procedure performed in the United States annually. Despite…

Series A $7.0M

InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…

Convertible Note $1.3M

Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…

Series A $10.0M

DeepCyte Funding FAQs

What does DeepCyte do?

DeepCyte is a biotechnology company that offers predictive products for toxicology using single-cell metabolomics technology.

How much funding has DeepCyte raised?

DeepCyte has raised $1.5M across 1 round on record. The most recent is a Seed of $1.5M announced in Apr 2026.

When did DeepCyte last raise funding?

DeepCyte's most recent funding round on record is a Seed of $1.5M, announced in Apr 2026.

Who founded DeepCyte?

FundedIQ lists Theodore Alexandrov (Founder) at DeepCyte.

Where is DeepCyte headquartered?

DeepCyte is based in Wilmington, Delaware, United States.

How many employees does DeepCyte have?

DeepCyte is in the 1-10 employee band.

How does DeepCyte's funding compare to other Biotechnology startups?

DeepCyte's latest round of $1.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.

About FundedIQ's DeepCyte Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DeepCyte is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.